PharmGKB summary: venlafaxine pathway

doi:10.1097/FPC.0000000000000003

Paper

PharmGKB summary: venlafaxine pathway

Published Jan 1, 2014 · K. Sangkuhl, J. Stingl, M. Turpeinen

Pharmacogenetics and Genomics

Q1 SJR score

57

Citations

4

Influential Citations

Full textSemantic Scholar

Abstract

Venlafaxine (VEN) is a serotonin–norepinephrine reuptake inhibitor marketed for the treatment of depression disorders. The molecular targets of VEN are the solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 (SLC6A4), and solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 (SLC6A2), resulting in an inhibition of serotonin and noradrenaline reuptake from the synaptic cleft. VEN also slightly inhibits dopamine reuptake. Therefore, those substances are available prolonged in the synaptic cleft for serotonergic and noradrenergic neurotransmission. VEN consists of a racemic mixture of R(+) and S(−) enantiomer. The (R) enantiomer has been shown to show greater serotonin reuptake inhibition property, whereas the (S) enantiomer inhibits the reuptake of both monoamines [1,2].

Study Snapshot

Venlafaxine (VEN) is a serotonin-norepinephrine reuptake inhibitor that prolongs serotonergic and noradrenergic neurotransmission in depression treatment by inhibiting serotonin and noradrenaline reuptake from the synaptic

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

PharmGKB summary: venlafaxine pathway

References

Citations